Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2008 3
2009 2
2010 2
2011 4
2012 7
2013 6
2014 5
2015 11
2016 12
2017 15
2018 5
2019 6
2020 9
2021 13
2022 11
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C; EORTC Melanoma Group. Eggermont AMM, et al. Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857412 Clinical Trial.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Bottomley A, et al. Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857414 Clinical Trial.
[Ipilimub for advanced melanoma].
Kiyohara Y. Kiyohara Y. Gan To Kagaku Ryoho. 2015 Apr;42(4):439-42. Gan To Kagaku Ryoho. 2015. PMID: 26020985 Japanese. No abstract available.
Translocation of the MAML2 gene in hidradenocarcinoma.
Yoshimi K, Goto H, Otsuka M, Yoshikawa S, Omodaka T, Kiyohara Y. Yoshimi K, et al. Among authors: kiyohara y. J Dermatol. 2017 Aug;44(8):e190-e191. doi: 10.1111/1346-8138.13830. Epub 2017 Mar 11. J Dermatol. 2017. PMID: 28295544 No abstract available.
Treatment strategy for cutaneous apocrine carcinoma.
Ogata D, Kiyohara Y, Yoshikawa S, Kasami M. Ogata D, et al. Among authors: kiyohara y. Int J Clin Oncol. 2014 Aug;19(4):712-5. doi: 10.1007/s10147-013-0594-x. Epub 2013 Jul 31. Int J Clin Oncol. 2014. PMID: 23900624
101 results